TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining relatively low systemic toxicity. The antitumor activity, different dosing sequences, and dosing regimens of TH-302 in combination with commonly used conventional chemotherapeutics were investigated in human tumor xenograft models.Methods Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer.Results The antitumor activity of docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide was increased when combined with TH-302 in nine out of eleven models tested. Administration of TH-302 2-8 h prior to the other chemotherapeutics yielded superior efficacy versus other sequences tested. Simultaneous administration of TH-302 and chemotherapeutics increased toxicity versus schedules with dosing separations. In a dosing optimization study, TH-302 administered daily at 50 mg/kg intraperitoneally for 5 days per week in the H460 NSCLC model showed the optimal response with minimal toxicity.Conclusions TH-302 enhances the activity of a wide range of conventional anti-neoplastic agents in a broad panel of in vivo xenograft models. These data highlight in vivo effects of schedule and order of drug administration in regimen efficacy and toxicity and have relevance to the design of human regimens incorporating TH-302.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the HAP evofosfamide (also known as TH-302) was reported to enhance the anticancer activity of chemotherapy drugs in mouse xenograft models of various cancer types, including CRC [216].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Major reasons for hypoxic tumor tissue resistance to chemotherapy include their distance from blood vessels and slower rate of proliferation [4, 26].”
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Doxorubicin is a poor tissue penetrator, and multiple previous studies have documented its inability to reach the hypoxic tumor compartment efficiently [28, 31].”
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“Hypoxic regions are common in tumors and contribute to malignant progression, metastasis and often resistance to both chemotherapy and radiotherapy [12, 43].”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240 · cited 1×
“The magnitude of tumor hypoxia measured in patients’ tumor tissue correlates with reduced survival [40].”
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686 · cited 1×
“The faster tumor regrowth kinetics that we observed with doxorubicin, cisplatin, irinotecan, and gemcitabine may be due to the selective sparing of stem cells in the hypoxic regions of xenografts [22, 39].”
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499 · cited 2×
“, doxorubicin and mitoxantrone [31, 38]; others exhibit low activity on slowly proliferating cells, e.”
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380 · cited 1×
“Hypoxia-activated compounds that have progressed to clinical trials for the treatment of cancer include tirapazamine [32], AQ4N [29], PR-104 [17], and TH-302 [41].”
Cited by
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
“For instance, it has been observed that a hypoxia-activated pro-drug designated as TH-302, which selectively targets hypoxic regions of solid tumours in combination with conventional chemotherapeutic drugs such as gemcitabine-induced greater anti-tumoral effects on diverse human tumour xenograft models including pancr…”
BackgroundMejia Oneto, J. M., Khan, I., Seebald, L., & Royzen, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00150 · Cited by 215
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
“TH-302, a hypoxia-induced pro-drug (HAP), functions as a DNA alkylating agent to induce damage and cell death [450].”
BackgroundBorad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W.-H., Wu, D.-H., Smaill, J. B., Patterson, A. V., & Ding, K. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10285 · Cited by 170
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, N., & Konopleva, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0895 · Cited by 138
Fu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
Rajendran, J. G., & Krohn, K. A. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.006 · Cited by 125
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Xu, Y., Song, G., Xie, S., Jiang, W., Chen, X., Chu, M., Hu, X., & Wang, Z. P. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.029 · Cited by 131
Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., van Stiphout, R. G. P. M., Yaromina, A., Sun, J. D., Hart, C. P., Windhorst, A. D., van Elmpt, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0018 · Cited by 120
Self-citationJoosten, S. C., Hamming, L. C., Soetekouw, P. M. M. B., Aarts, M. J. B., Veeck, J., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.002 · Cited by 119
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
Schöffski, P., Cornillie, J., Woźniak, A., Li, H., & Hompes, D. (2014) · Oncology Research and Treatment · doi:10.1159/000362631 · Cited by 112
Therapeutic Targeting of Hyaluronan in the Tumor Stroma
Kultti, A., Li, X., Jiang, P., Thompson, C. B., Frost, G. I., & Shepard, H. M. (2012) · Cancers · doi:10.3390/cancers4030873 · Cited by 105
“pancreatic adenocarcinoma (PDA) [8]; and TH-302, a hypoxia-activated prodrug which has also been shown to increase the antitumor activity of a broad range of conventional chemotherapy agents in human xenograft models and for which clinical testing is ongoing [9,10].”
BackgroundHypoxia-activated prodrugs and redox-responsive nanocarriers
Zeng, Y., Ma, J., Zhan, Y., Xu, X., Zeng, Q., Liang, J., & Chen, X. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173431 · Cited by 106
Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
Higgins, G. S., O'Cathail, S. M., Muschel, R. J., & McKenna, W. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.012 · Cited by 107
“TH-302 has been shown to augment the cell killing toxicity of several chemotherapeutics pre-clinically, and has been safely combined with doxorubicin in a phase II trial [22,23].”
BackgroundMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, the HAP evofosfamide (also known as TH-302) was reported to enhance the anticancer activity of chemotherapy drugs in mouse xenograft models of various cancer types, including CRC [216].”
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
Wojtkowiak, J. W., Cornnell, H. C., Matsumoto, S., Saito, K., Takakusagi, Y., Dutta, P., Kim, M., Zhang, X., Leos, R. A., Bailey, K. M., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-014-0026-z · Cited by 79
“TH-302 is highly effective in preclinical pancreatic models [15] and has been effective in phase I/II trials in combination with gemcitabine (GEM), increasing progression-free survival of late-stage cancers by 2 months [16].”
Self-citationHypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Benito, J., Ramirez, M. S., Zacharias, N. M., Vélez, J., Harutyunyan, K. G., Lu, H., Shi, Y.-X., Matre, P. R., Jacamo, R. O., Ma, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3378 · Cited by 82
“We also demonstrated that TH-302 has synergistic and additive effects in combination with conventional chemotherapy and demethylating agents in vitro, as has been observed in preclinical solid tumor models(55).”
Self-citationSilva, V. L., & Al-Jamal, W. T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.013 · Cited by 78
“Phase I/II clinical trials have shown promising results for the drug as both a single agent and in combinatorial treatments with gemcitabine and nab-paclitaxel for pancreatic cancer [67,68,76].”
BackgroundThe Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Li, Y., Zhao, L., & Li, X.-F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.636892 · Cited by 70
“Combination of TH-302 With Conventional Chemotherapy TH-302 has been shown to enhance the anti-tumor effect of many conventional chemotherapy drugs, such as docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, temozolomide, and topotecan (Liu et al., 2012; Saggar and Tannock, 2014; Liapis et al., 20…”
BackgroundHypoxia, a key factor in the immune microenvironment
Hu, J., Li, X., Yang, L., & Li, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113068 · Cited by 68
Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance
Dratkiewicz, E., Simiczyjew, A., Mazurkiewicz, J., Ziętek, M., Matkowski, R., & Nowak, D. (2021) · Cells · doi:10.3390/cells10040862 · Cited by 76
Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., DeNichilo, M., Ingman, W., Atkins, G. J., Findlay, D. M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.020 · Cited by 56
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
Muz, B., de la Puente, P., Azab, F., Luderer, M. J., & Azab, A. K. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0028 · Cited by 66
Saggar, J. K., & Tannock, I. F. (2014) · International Journal of Cancer · doi:10.1002/ijc.28595 · Cited by 58
New ways to image and target tumour hypoxia and its molecular responses
Dubois, L. J., Niemans, R., van Kuijk, S. J. A., Panth, K. M., Parvathaneni, N.-K., Peeters, S. G. J. A., Zegers, C. M. L., Rekers, N. H., van Gisbergen, M. W., Biemans, R., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.022 · Cited by 60
“models [23–26].”
Dai, C., Zhang, B., Liu, X., Ma, S., Yang, Y., Yao, Y., Feng, M., Bao, X., Li, G., Wang, J., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1908 · Cited by 62
Self-citationJamieson, S. M. F., Tsai, P., Kondratyev, M. K., Budhani, P., Liu, A. J., Senzer, N. N., Chiorean, E. G., Jalal, S. I., Nemunaitis, J. J., Kee, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122204 · Cited by 61
Self-citationSun, J. D., Liu, Q., Ahluwalia, D., Li, W., Meng, F., Wang, Y., Bhupathi, D., Ruprell, A. S., & Hart, C. P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1003005 · Cited by 53
“TH-302 exhibits hypoxia-selective in vitro cytotoxicity cross a wide variety of human cancer cell lines(19) and in vivo anti-tumor efficacy in a panel of human tumor xenograft models.(20,21) Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors in humans, with a 5-year survival rate of less than…”
BackgroundMethodSelf-citationSaggar, J. K., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2298 · Cited by 52
“p 4 hours before chemotherapy; this was based on previous studies establishing greater tumor cell death, DNA damage (7), and increased growth delay (18) in this administration.”
MethodMetran-Nascente, C., Yeung, I. W. T., Vines, D. C., Metser, U., Dhani, N. C., Green, D., Milosevic, M., Jaffray, D. A., & Hedley, D. W. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167650 · Cited by 54
“Pancreatic cancers are commonly believed to be unusually hypoxic, perhaps explaining in part their aggressive biology and poor response to standard treatments (1–7) and providing a rationale for treatment protocols incorporating hypoxia-targeted agents (8).”
BackgroundTargeting Hypoxia in the Leukemia Microenvironment
Benito, J., Zeng, Z., Konopleva, M. Y., & Wilson, W. R. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.32 · Cited by 54
Hypoxia-Sensitive Materials for Biomedical Applications
Yu, J., Zhang, Y., Hu, X., Wright, G., & Gu, Z. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1578-6 · Cited by 52
Kishimoto, S., Brender, J., Chandramouli, G. V. R., Saida, Y., Yamamoto, K., Mitchell, J. B., & Krishna, M. C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8131 · Cited by 50
Herdman, C. A., Strecker, T. E., Tanpure, R. P., Chen, Z., Winters, A., Gerberich, J., Liu, L., Hamel, E., Mason, R. P., Chaplin, D. J., et al. (2016) · MedChemComm · doi:10.1039/c6md00459h · Cited by 50
Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates
Xiao, D., Liu, L., Xie, F., Dong, J., Wang, Y., Xu, X., Zhong, W., Deng, H., Zhou, X., & Li, S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202310318 · Cited by 48
Self-citationLiu, X.-W., Cai, T.-Y., Zhu, H., Cao, J., Su, Y., Hu, Y.-Z., He, Q.-J., & Yang, B. (2013) · Autophagy · doi:10.4161/auto.26838 · Cited by 48
“For example, it was reported that TH-302 enhanced the anticancer activity of doxorubicin in a broad panel of in vivo xenograft models including nonsmall cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer.(25) Thus this increased understanding of hypoxia-targeted dual…”
BackgroundRecent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Yin, L., Hu, Q., & Hartmann, R. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713958 · Cited by 49
“Fewer side effects are therefore expected than observed after other chemotherapies [79].”
BackgroundInfluentialBadar, T., Handisides, D. R., Benito, J. M., Richie, M. A., Borthakur, G. M., Jabbour, E. J., Harutyunyan, K. G., Konoplev, S. N., Faderl, S. H., Kroll, S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24415 · Cited by 47
“Studies in solid tumors and other hematological malignancies have shown additive advantage when evofosfamide is used with combination chemotherapy [23,32,33].”
BackgroundLaubach, J. P., Liu, C., Raje, N. S., Yee, A. J., Armand, P. A., Schlossman, R. L., Rosenblatt, J. M., Hedlund, J. A., Martin, M. G., Reynolds, C. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1325 · Cited by 49
Wu, S., Fan, K. S., Yang, Q., Chen, Z., Hou, Y., Zou, Y., Cai, W., & Kang, L. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01804-7 · Cited by 46
“TH-302 prodrugs can be rapidly converted into active components under hypoxic conditions of the TME to kill tumor cells [95].”
BackgroundHypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Robles-Oteíza, C., Hastings, K., Choi, J., Sirois, I., Ravi, A., Expósito, F., de Miguel, F. J., Knight, J., López‐Giráldez, F., Choi, H., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231106 · Cited by 46
“TH-302 (#ATE448430720; Sigma-Aldrich) was delivered continuously every other day via i.p. injection at 50 mg/kg (Liu et al., 2012; Jayaprakash et al., 2018).”
Chintamaneni, P. K., Pindiprolu, S. K. S. S., Swain, S. S., Karri, V. V. S. R., Nesamony, J., Selvam, C., & Bhaskaran, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216782 · Cited by 46
Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice
Kishimoto, S., Brender, J. R., Crooks, D. R., Matsumoto, S., Seki, T., Oshima, N., Merkle, H., Lin, P., Reed, G., Chen, A. P., et al. (2019) · eLife · doi:10.7554/elife.46312 · Cited by 41
“Beyond the Warburg effect, researchers have begun to target other vulnerable aspects of PDAC metabolism such as amino acid synthesis (Ananieva, 2015) or the unique chemical environment of tumors by hypoxia activated prodrugs (Bailey et al., 2014; Liu et al., 2012).”
BackgroundHajj, C., Russell, J., Hart, C. P., Goodman, K. A., Lowery, M. A., Haimovitz‐Friedman, A., Deasy, J. O., & Humm, J. L. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.06.010 · Cited by 41
Self-citationRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
Ulivi, P., Marisi, G., & Passardi, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8712 · Cited by 42
“There are 4 phase I/II clinical trials combining the hypoxia activated prodrug TH-302, an alkylating agent with an anti-angiogenic therapy in a variety of tumors (NCT01497444, NCT01381822, NCT01403610, NCT01485042) [118].”
BackgroundPerspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
Nytko, K. J., Grgic, I., Bender, S., Ott, J., Gückenberger, M., Riesterer, O., & Pruschy, M. N. (2017) · Oncotarget · doi:10.18632/oncotarget.15784 · Cited by 39
Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs
Jackson, R. K., Liew, L. P., & Hay, M. P. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.02.004 · Cited by 39
Tercel, M., Lee, H. H., Mehta, S. Y., Youte, J., Bai, S. Y., Liyanage, H. D. S., & Pruijn, F. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00563 · Cited by 37
Zhang, L., Marrano, P. M., Wu, B. H., Kumar, S., Thorner, P. S., & Baruchel, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1853 · Cited by 35
“Consequently, evofosfamide can target the malignant cells residing in hypoxic zones, while having little or no cytotoxic effect on the normal cells (14, 15).”
BackgroundHypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma
Wang, Z., Li, Q., & Liang, B. (2024) · Pharmaceuticals · doi:10.3390/ph17081057 · Cited by 36
GdDO3NI, a nitroimidazole-based T 1 MRI contrast agent for imaging tumor hypoxia in vivo
Gulaka, P., Rojas‐Quijano, F. A., Kovács, Z. Z., Mason, R. P., Sherry, A. D., & Kodibagkar, V. D. (2013) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1058-5 · Cited by 37
Takakusagi, Y., Kishimoto, S., Naz, S., Matsumoto, S., Saito, K., Hart, C. P., Mitchell, J. B., & Krishna, M. C. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7106 · Cited by 34
“studies, it has been shown to improve the overall response when used in combination therapy with antiproliferative agents (14, 19, 21, 22).”
BackgroundSelf-citationYoon, C., Lee, H.-J., Park, D. J., Lee, Y., Tap, W. D., Eisinger‐Mathason, T. S. K., Hart, C. P., Choy, E., Simon, M. C., & Yoon, S. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.186 · Cited by 31
“…enhances the activity of a wide range of chemotherapy drugs in numerous xenograft models including HT1080 xenografts (Liu et al, 2012; Sun et al, 2012b), and has been found to be a promising agent in combination with doxorubicin for patients with metastatic sarcoma…”
BackgroundSelf-citationLarue, R. T. H. M., Voorde, L. V. D., Berbée, M., van Elmpt, W., Dubois, L. J., Panth, K. M., Peeters, S. G. J. A., Claessens, A., Schreurs, W. M. J., Nap, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2709-z · Cited by 30
“Evofosfamide (TH-302) is a hypoxia-activated prodrug only activated under low levels of oxygen (hypoxia) [17–23].”
Sun, J. D., Liu, Q., Ahluwalia, D., Ferraro, D. J., Wang, Y., Jung, D. T., Matteucci, M. D., & Hart, C. P. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139268 · Cited by 30
Self-citationPreclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Durán, R., Mirpour, S., Pekurovsky, V., Ganapathy‐Kanniappan, S., Brayton, C. F., Cornish, T. C., Gorodetski, B., Reyes, J., Chapiro, J., Schernthaner, R. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0725 · Cited by 30
“Here we demonstrated that evofosfamide combined with cTACE achieved better anticancer efficacy than cTACE supporting the added benefit of combining doxorubicin and evofosfamide as reported in preclinical and clinical studies (14, 19, 44).”
BackgroundSelf-citationBailey, K. M., Cornnell, H. H., Ibrahim‐Hashim, A., Wojtkowiak, J. W., Hart, C. P., Zhang, X., Leos, R. A., Martinez, G. V., Baker, A. F., & Gillies, R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113586 · Cited by 30
Self-citationEnhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
Meng, F., Bhupathi, D., Sun, J. D., Liu, Q., Ahluwalia, D., Wang, Y., Matteucci, M. D., & Hart, C. P. (2015) · BMC Cancer · doi:10.1186/s12885-015-1387-6 · Cited by 28
“Notable among these are the ATP-competitive inhibitors LY2603618, PF477736, AZD7762, SCH90077617, and LY260636818 [5], the latter three of which have progressed to Phase II clinical trials.”
BackgroundSelf-citationSun, J. D., Ahluwalia, D., Liu, Q., Li, W., Wang, Y., Meng, F., Bhupathi, D., Matteucci, M. D., & Hart, C. P. (2015) · Europe PMC (PubMed Central) · Cited by 26
Self-citationCárdenas‐Rodríguez, J., Li, Y., Galons, J., Cornnell, H. H., Gillies, R. J., Pagel, M. D., & Baker, A. F. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.02.015 · Cited by 26
Self-citationZhang, X., Wojtkowiak, J. W., Martinez, G. V., Cornnell, H. H., Hart, C. P., Baker, A. F., & Gillies, R. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155289 · Cited by 25
“[40] So the reduction of permeability could be the consequence of TH-302 activation under the low oxygen conditions resulting in inhibition of VEGF signaling.”
BackgroundSelf-citationHypoxia-Directed Drug Strategies to Target the Tumor Microenvironment
Hay, M. P., Hicks, K. O., & Wang, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_6 · Cited by 26
Self-citationStokes, A. M., Hart, C. P., & Quarles, C. C. (2016) · Tomography · doi:10.18383/j.tom.2016.00259 · Cited by 25
“studies have shown broad in vivo activity and efficacy of evofosfamide both as monotherapy or in combination with other chemotherapeutics in preclinical (18, 20-24) and clinical (19, 25, 26) studies.”
BackgroundSelf-citationLindquist, K. E., Cran, J., Kordic, K., Chua, P. C., Winters, G. C., Tan, J. S., Lozada, J., Kyle, A. H., Evans, J., & Minchinton, A. I. (2013) · Tumor Microenvironment and Therapy · doi:10.2478/tumor-2013-0003 · Cited by 23
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1715 · Cited by 22
Self-citationHuang, Y., & Carbone, D. P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.003 · Cited by 24
Yoon, C., Chang, K. K., Lee, J. H., Tap, W. D., Hart, C. P., Simon, M. C., & Yoon, S. S. (2016) · Oncotarget · doi:10.18632/oncotarget.10212 · Cited by 22
Self-citationRetractedHarms, J. K., Lee, T. W., Wang, T., Lai, A., Kee, D., Chaplin, J. M., McIvor, N., Hunter, F. W., Macann, A., Wilson, W. R., et al. (2019) · Cells · doi:10.3390/cells8070717 · Cited by 22
Kumar, S., Sun, J. D., Zhang, L., Mokhtari, R. B., Wu, B. H., Meng, F., Liu, Q., Bhupathi, D., Wang, Y., Yeger, H., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.004 · Cited by 19
“It is reported to enhance the cytotoxicity of cytotoxic agents in preclinical models of non–small cell lung cancer (NSCLC), colon cancer, prostate cancer, melanoma, fibrosarcoma, and pancreatic cancer [10].”
BackgroundSelf-citationHypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere
Ma, P., Chen, J., Qu, H., Li, Y., Li, X., Tang, X., Song, Z., Xin, H., Zhang, J., Nai, J., et al. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831102 · Cited by 19
Hunter, F. W., Devaux, J. B. L., Meng, F., Hong, C. R., Khan, A., Tsai, P., Ketela, T. W., Sharma, I., Kakadia, P. M., Marastoni, S., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.115196 · Cited by 18
“…(Jamieson et al., 2018; Jayaprakash et al., 2018), bortezomib (Hu et al., 2013), mTOR (mammalian target of rapamycin) inhibitors (Sun et al., 2015), transarterial chemoembolisation (Duran et al., 2017), and various cytotoxic agents (Liu et al., 2012; Zhang et al., 2016; Haynes et al., 2018).”
BackgroundSelf-citationInvestigational Hypoxia-Activated Prodrugs: Making Sense of Future Development
Su, M., Zhang, L., Huang, Z., Shi, J.-J., & Lu, J. (2018) · Current Drug Targets · doi:10.2174/1389450120666181123122406 · Cited by 18
Meaney, C., Rhebergen, S., & Kohandel, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007926 · Cited by 17
“Numerous experimental preclinical studies have analyzed the use of HAPs alone or in combination with other therapies, showing positive outcomes for the control of tumour growth and invasion in a number of different tumour types ([12, 13, 17–22] for example).”
Tang, J., Chang, H., & Chang, J. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.1998 · Cited by 18
“Accordingly, when TH-302 is used in a combination with other conventional antineoplastic agents, the efficacy of TH-302 is affected by the order in which it is administered (Liu et al., 2012).”
BackgroundHamis, S., Kohandel, M., Dubois, L. J., Yaromina, A., Lambin, P., & Powathil, G. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008041 · Cited by 15
“Thus hypoxia may both protect and progresses solid tumours [12, 13] and, accordingly, severe tumour hypoxia is associated with tumours that are difficult to treat and, by extension, poor prognoses for patients [2, 7].”
Xiao, R., Jin, L., Xie, N., Luo, P., Gao, W., Tu, P., & Ai, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1032975 · Cited by 14
“Take the docetaxel as an example, 5–15 mg/kg dosage was recommended previously (Liu et al., 2012; Wallin et al., 2012; Tan et al., 2015).”
BackgroundMethodExploiting tumor hypoxia for cancer treatment
Niemans (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20180626rn · Cited by 14
Realistic biological approaches for improving thermoradiotherapy
Horsman, M. R. (2015) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1099169 · Cited by 13
“However, to date the only bioreductive drug in clinical evaluation is the nitroaromatic compound TH-302 [22], but the preclinical [23] and clinical [22] studies have focused on its combination with chemotherapy rather than radiation, and certainly not hyperthermia.”
BackgroundRole of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach
Meaney, C., Powathil, G., Yaromina, A., Dubois, L. J., Lambin, P., & Kohande, M. (2019) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2019312 · Cited by 13
Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma
Bhaw‐Luximon, A., Goonoo, N., & Jhurry, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42863-7.00006-2 · Cited by 12
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000
Mao, X., McManaway, S. P., Jaiswal, J. K., Hong, C. R., Wilson, W. R., & Hicks, K. O. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1617570 · Cited by 13
“TH-302 is generally more active when dosed before cytotoxic drugs in xenograft models, although in the combination with gemcitabine there was no significant time dependence of activity against H460 tumors but enhanced host toxicity with co-administration.(40) In a randomized Phase II trial of gemcitabine plus TH-302 a…”
BackgroundBailleul, Q., Navarin, P., Arcicasa, M., Mahieu, C., Carcaboso, A. M., Bourhis, X. L., Furlan, A., Meignan, S., & Leblond, P. (2021) · Cancers · doi:10.3390/cancers13081804 · Cited by 13
“These results are consistent with previous studies, which demonstrated an antitumor effect of Evo used in combination with doxorubicin in a mouse model of non-small cancer cell lung xenograft [16].”
BackgroundResultWestwood, L., Nixon, I. J., Emmerson, E., & Callanan, A. (2024) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2024.1347324 · Cited by 14
Otowa, Y., Kishimoto, S., Saida, Y., Yamashita, K., Yamamoto, K., Chandramouli, G. V. R., Devasahayam, N., Mitchell, J. B., Krishna, M. C., & Brender, J. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0118 · Cited by 9
Discovery of the Hypoxia-Activated Prodrug SN30000
Hay, M. P., Hicks, K. O., & Wilson, W. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12450-3 · Cited by 7
18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
Grkovski, M., Fanchon, L. M., Pillarsetty, N., Russell, J., & Humm, J. L. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0409-1 · Cited by 6
“Evofosfamide (TH302) is a hypoxia-activated prodrug that showed promise against pancreatic cancer in preclinical and phase II trials [1, 2].”
BackgroundYoon, J., Kang, S. Y., Lee, K.-H., Cheon, G. J., & Oh, D. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.577 · Cited by 6
Das, S., Venkatesh, G. H., El‐Sayed, W., Khouzam, R. A., Mahmood, A. S., Nawafleh, H. H., Zeinelabdin, N. A., Zaarour, R. F., & Chouaïb, S. (2025) · Cancers · doi:10.3390/cancers17121988 · Cited by 5
“Evofos has been evaluated as a treatment for various cancer types, both as a monotherapy and in combination with agents such as cisplatin, doxorubicin, temozolomide, and radiation therapy [7,8].”
Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma
Babiker, H. M., Riaz, I. B., Shah, S., Hoff, D. D. V., & Borad, M. J. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000437 · Cited by 5
Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates
Xiao, D., Liu, L., Xie, F., Dong, J., Wang, Y., Xu, X. M., Zhong, W., Deng, H., Zhou, X., & Li, S. (2024) · Angewandte Chemie · doi:10.1002/ange.202310318 · Cited by 6
Self-citationProdrug Strategies for Targeting Tumour Hypoxia
Wilson, W. R., Hicks, K. O., Wang, J., & Pruijn, F. B. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_13 · Cited by 2
“In a comprehensive study involving 11 xenograft models and seven different chemotherapy agents (Liu et al. 2012), combination with TH-302 was well tolerated and in each case showed a trend to greater anti-tumour activity compared to chemotherapy alone; this increase was statistically significant for 4 of 15 combinatio…”
BackgroundSelf-citationAgarwal, S., Damodaran, L., Inge, L. J., & Kodibagkar, V. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-32618-2 · Cited by 2
Industry progress report on neuro-oncology: a biotech update
Haber, J. S., Banu, M. A., Ray, A. E., Kesavabhotla, K., & Boockvar, J. A. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1036-8 · Cited by 2
“Tissue hypoxia promotes the release of Br-IPM, a DNAalkylating agent [11, 24].”
BackgroundSchuitmaker, L., van der Wiel, A. M.-M. A., Lieuwes, N. G., Biemans, R., Mutsters, N. A. M., Jung, J., Bastos, V. C., Prades-Sagarra, È., Kuang, S., Setton, J. S., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201161 · Cited by 1
Overcoming tumor hypoxia: factors influencing the efficacy of the hypoxia-activated prodrug CP-506
van der Wiel, A. M.-M. A. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230202aw · Cited by 1
The hypoxic tumor microenvironment: from imaging to targeting
Peeters, S. G. J. A. (2015) · Research Publications (Maastricht University) · doi:10.26481/dis.20150709sp
The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs
Benito, J., Konopleva, M. Y., & Wilson, W. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_35
Metadata
- Authors
- Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., & Hart, C. P.
- Affiliations
- Threshold Pharmaceuticals (United States) (US)
- University of Arizona (US)
- Corresponding author
- Hart, Charles P.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2012-03-02
- Volume
- 69
- Issue
- 6
- Pages
- 1487-1498
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC3985381
- OpenAlex
- W2087565365
- Cited by
- 113
- References
- 45
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 8 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 13 · 2012: 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA95060, R01CA125627, P50CA095060, P30CA023074)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- TH-302, hypoxia-activated prodrug, tumor hypoxia, combination chemotherapy, dosing regimen, dosing regimen optimization, chemotherapy toxicity, non-small cell lung cancer, xenograft models, docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, temozolomide
- MeSH terms
- Pemetrexed, Docetaxel, Irinotecan, Gemcitabine, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cisplatin, Deoxycytidine, Drug Evaluation, Preclinical, Glutamates, Guanine, Humans, Nitroimidazoles, Phosphoramide Mustards, Prodrugs, Cell Hypoxia, Mice, SCID, Xenograft Model Antitumor Assays, Taxoids, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.